×

Biotech and Pharmaceuticals Pharmaceuticals

  • NEW YORK, Feb 8- Tetraphase Pharmaceuticals Inc Chief Executive Guy Macdonald said annual sales of the company's lead experimental antibiotic for serious bacterial infections could climb as high as $700 million if approved. "The FDA has been very supportive of getting new antibiotics approved, so clearly we have a fast-track agreement with them once we get...

  • Martin Shkreli, former Chief Executive Officer of Turing Pharmaceuticals

    A new SEC filing shows that Shkreli is involved in a tech start-up whose executives include a long-time Shkreli associate.

  • Sales of the drugs, including Sovaldi and Harvoni, have slowed, missing Wall Street estimates in the past few quarters, but still account for nearly half of Gilead's total revenue. Chief Executive John Milligan acknowledged on Tuesday that the company had few prospects for new products over the next few years. The company had $32.4 billion of cash, cash...

  • Feb 8- U.S. biopharmaceutical company Tesaro Inc is discussing its options with investment banks after receiving acquisition interest from several drugmakers, according to people familiar with the matter. Tesaro shares rose as much as 17 percent on the news and were up 11 percent at $180.50 in late morning trading in New York on Wednesday, giving the company a...

  • Feb 8- U.S. biopharmaceutical company Tesaro Inc is discussing its options with investment banks after receiving acquisition interest from several drug makers, according to people familiar with the matter. Tesaro is not actively exploring a sale, the people said this week, noting that there is a significant gap over the company's valuation between Tesaro and...

  • Gilead stock slips on soft hepatitis C sales forecast

    Shares of Gilead Sciences are in the red after the drugmaker issued a weak sales forecast for its hepatitis C drugs.

  • Feb 8- Allergan Plc Chief Executive Brent Saunders said on Wednesday he does not anticipate U.S. tax reforms this year and that a border-adjustment tax could have a detrimental impact on the Dublin- based drugmaker. House Speaker Paul Ryan said last week that U.S. House Republicans are unlikely to begin tackling tax reform legislation until the summer, focusing...

  • *India sales up 19 pct. MUMBAI, Feb 8- Indian drugmaker Cipla Ltd's third-quarter profit beat estimates due to higher sales in the United States, and the company said it was looking for licensing deals and acquisitions to build its speciality medicines pipeline in that market. Cipla's Goa drug factory failed manufacturing standards during an FDA inspection...

  • *Q4 2016 core EPS 26.1 pence vs consensus forecast 25.0 p. LONDON, Feb 8- GlaxoSmithKline quarterly sales and profits beat expectations, buoyed by a weak pound, but the drugmaker warned earnings stripping out currencies could slip in 2017 if generic copies of its lung drug Advair arrive in the United States. Quarterly sales rose 21 percent in sterling terms to 7.59...

  • GSK CEO: US health care system could benefit from more transparency

    Sir Andrew Witty, GlaxoSmithKline CEO, discusses prescription drug prices and how to keep costs under control while promoting innovation.

  • GSK beats Street on top and bottom line

    CNBC's Meg Tirrell breaks down GlaxoSmithKline's quarterly results.

  • LONDON— Pharmaceutical company GlaxoSmithKline saw its sales and profits grow in the fourth quarter but warned that tougher competition from generic drugmakers could depress its earnings this year. The London- based company said Wednesday its net income rose to 257 million pounds, from a loss of 354 million pounds a year earlier. Outgoing CEO Andrew Witty,...

  • Feb 8- Two remaining late-stage clinical trials testing an experimental Alzheimer's drug from Denmark's Lundbeck have failed, scuppering hopes for the medicine and underscoring the difficulty of developing such treatments. Lundbeck's idalopirdine is a so-called 5- HT6 antagonist and is similar to another pill, called intepirdine, being developed by U.S....

  • PARIS, Feb 8- France's biggest drugmaker, Sanofi, which missed out to Johnson& Johnson on buying Actelion last month, said it was no rush to do deals as it forecast stable or slightly lower 2017 earnings. "In 2017 and beyond we will continue to simplify and reshape the company," Chief Executive Olivier Brandicourt told journalists. Sanofi shares were up 2.6 percent in...

  • PARIS, Feb 8- France's biggest drugmaker, Sanofi, which missed out on a major takeover deal last month, said on Wednesday it expected 2017 earnings per share to be stable or slightly lower. "In 2017 and beyond we will continue to simplify and reshape the company," Chief Executive Olivier Brandicourt told journalists. Under pressure from investors to land a...

  • PARIS, Feb 8- Sanofi, France's largest drugmaker, said it expected 2017 earnings per share to be stable or slightly lower after its fourth quarter results were affected by an increase in taxes and one-off charges. Sanofi said fourth-quarter business net income fell 2.9 percent at constant exchange rates to 1.61 billion euros. Total sales rose 3.4 percent to 8.87...

  • Novasecta Engagement Manager Brian McGee discusses pharmaceutical firm GlaxoSmithKline and where it’s heading going forward as it takes on a new CEO.

  • An employee collects newly-manufactured pills at Teva Pharmaceutical Industries.

    Shares of Teva slipped more than 6 percent after announcing that its CEO will step down and reports of a bribery investigation.

  • People attend an afternoon rally in Battery Park to protest U.S. President Donald Trump's new immigration policies on January 29, 2017 in New York City.

    Jeremy Levin, Ovid Therapeutics CEO, former Teva Pharmaceuticals CEO, speaks to CNBC's Meg Tirrell about how President Trump's immigration plans may impact the biotech industry.

  • ViroPharma, which has since been purchased by Shire PLC, began filing petitions with the FDA in 2006 when the agency set a streamlined procedure for proving that generic rivals were the same chemically as Vancocin, whose active ingredient is vancomycin hydrochloride. The FDA had been prepared to approve a generic version in 2010 but the blizzard of filings...